US Tecfidera Sales Could Plunge By $2.8bn In 2021
Market Reacts To Mylan ‘At-Risk’ Launch
Generic competition to the one of the most lucrative small-molecule opportunities in the US arrived as Mylan pushed on with an “at-risk” launch to Biogen’s Tecfidera. Mylan’s fortunes and the ramifications of parallel litigation in a separate court were speculated by investors in the wake of the news.
You may also be interested in...
FDA’s OGD Takes Fight To COVID-19 With Half-Century Of Approvals
The sixth annual report of the FDA’s Office of Generic Drugs covered a year dominated by the novel coronavirus pandemic – although first-time generic approvals and record levels of communication also featured prominently.
Biosimilars Rise Is Cold Comfort For Biogen As Tecfidera Competition Bites
Biosimilars sales rising by 8% to almost $800m in 2020 failed to offset the impact on Biogen of generic competition to its Tecfidera brand in the US.
Floodgates Open For Tecfidera Rivals
Following Mylan’s initial launch of a generic rival to Biogen’s $3.8bn Tecfidera brand, other generics companies are now following the firm into the US dimethyl fumarate market.